Ethyl-EPA

Ethyl-EPA Uses, Dosage, Side Effects, Food Interaction and all others data.

Ethyl-EPA or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). It is used as adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL). FDA approved on July 26, 2012.

Ethyl-EPA
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Ethyl-EPA
Generic	Icosapent ethyl
Icosapent ethyl Other Names	E-EPA, Eicosapentaenoic acid ethyl ester, Ethyl eicosapentaenoate, Ethyl icosapentate, Ethyl-EPA, Icosapent ethyl, Timnodonic acid ethyl ester
Type
Formula	C₂₂H₃₄O₂
Weight	Average: 330.5042 Monoisotopic: 330.255880332
Groups	Approved, Investigational, Nutraceutical
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Ethyl-EPA is an ethyl ester of eicosapentaenoic acid (EPA) that reduces synthesis and enhances clearance of triglycerides that is used to treat patients with severe hypertriglyceridemia.

Ethyl-EPA is used as adjunct therapy to reduce triglyceride (TG) levels in adults with severe (>500 mg/dL) hypertriglyceridemia.

Ethyl-EPA is also used to associated treatment for these conditions: Severe Hypertriglyceridemia

How Ethyl-EPA works

Studies suggest that EPA reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles. Potential mechanisms of action include increased β-oxidation; inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT); decreased lipogenesis in the liver; and increased plasma lipoprotein lipase activity.

Toxicity

Ethyl-EPA is generally well tolerated and adverse effects are unrelated to treatment.

Food Interaction

Take with food.

Volume of Distribution

Steady state volume of distribution of active EPA is 88 L

Elimination Route

Ethyl-EPA is de-esterfied, converted into active EPA, and then absorbed in the small intestine. It reaches peak plasma concentration in 5 hours post-oral administration. Very little (<1%) is left circulating in the plasma as EPA incorporates into phospholipids, TG's, and cholesteryl esters.